Clinical trial: Investigational anti-amyloid treatment started before Alzheimer’s symptoms did not slow memory loss

Preliminary results from a landmark clinical trial to prevent Alzheimer’s disease (AD) symptoms show that an investigational anti-amyloid drug, solanezumab, did not demonstrate a statistically significant slowing of cognitive decline associated with AD when initiated prior to the stage of clinical impairment.

Leave A Comment

Your email address will not be published. Required fields are marked *